NCT01601626: Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV |
|
|
| Terminated | 2b | 71 | RoW | Standard-dose Lopinavir/Ritonavir, LPV/RTV, LPV/r, Aluvia, Kaletra, Double-dose Lopinavir/Ritonavir, Raltegravir, RAL, Isentress, Isoniazid, INH, Pyridoxine, Vitamin B6, Pyrazinamide, PZA, Ethambutol, EMB, Rifabutin, RBT, Rifampin, RIF | AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infection, Tuberculosis | 01/17 | 06/17 | | |
NCT00822315: Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis |
|
|
| Completed | 2 | 155 | Europe, RoW | efavirenz, raltegravir | ANRS, Emerging Infectious Diseases, Gilead Sciences, Merck Sharp & Dohme LLC | HIV Infections, Tuberculosis | 11/11 | 05/12 | | |
